Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Roche is spend­ing $80 mil­lion up­front on a new prod­uct from ex­ist­ing part­ner In­novent Bi­o­log­ics. The DLL3-tar­get­ing can­di­date for small cell lung can­cer is the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER